Ertapenem

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz.[1]

Ertapenem
Clinical data
Trade namesInvanz
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
  • US: B (No risk in non-human studies)
    Routes of
    administration    		Intramuscular, intravenous
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Bioavailability90% (intramuscular)
    Protein bindingInversely proportional to concentration; 85 to 95%
    MetabolismMinor hydrolysis of beta-lactam ring, CYP not involved
    Elimination half-life4 hours
    ExcretionRenal (80%) and fecal (10%)
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC22H25N3O7S
    Molar mass475.516 g/mol g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    References
    1. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (November 2011). "Carbapenems: past, present, and future". Antimicrob. Agents Chemother. 55 (11): 4943–60. doi:10.1128/AAC.00296-11. PMC 3195018. PMID 21859938.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.